KR930006003A - 이미다졸릴메틸-피리딘류 화합물 - Google Patents

이미다졸릴메틸-피리딘류 화합물 Download PDF

Info

Publication number
KR930006003A
KR930006003A KR1019920017228A KR920017228A KR930006003A KR 930006003 A KR930006003 A KR 930006003A KR 1019920017228 A KR1019920017228 A KR 1019920017228A KR 920017228 A KR920017228 A KR 920017228A KR 930006003 A KR930006003 A KR 930006003A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
hydrogen
acid addition
halogen
Prior art date
Application number
KR1019920017228A
Other languages
English (en)
Other versions
KR100254085B1 (ko
Inventor
칼 안드레아스 기게르 루돌프
Original Assignee
예안 크레이머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예안 크레이머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 예안 크레이머, 한스 루돌프 하우스
Publication of KR930006003A publication Critical patent/KR930006003A/ko
Application granted granted Critical
Publication of KR100254085B1 publication Critical patent/KR100254085B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Luminescent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

하기 일반식(Ⅰ)의 화합물은 노인성치매층, 알쯔하이머 병 및 우울증 치료에 사용될 수 있다 ;
상기 일반식(Ⅰ)에서 R1내지 R4는 발명의 상세한 설명에서 정의된 것과 같다.

Description

이미다졸릴메틸-피리딘류 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(Ⅰ)로 표시되는 유기염기는 또는 산 부가 염 형태의 화합물 ;
    상기식에서 R1은 알킬(1-4C), 원자번호 9 내지 35에 해당하는 할로겐 또는 알킬(1-4C)에 의해 임의로 단일 또는 이치환된 아미노이고, R2및 R3는 서로 독립적으로 수소 또는 알킬(1-4C)이고 R4는 수소, 히드록시, 알킬(1-4C), 알콕시(1-4C) 또는 원자번호 9 내지 35에 해당하는 할로겐이다.
  2. 제1항에 있어서, R1은 알킬(1-4C)이고, R2및 R3는 서로 독립적으로 수소 또는 알킬(1-4C)이며 R4는 수소, 알킬(1-4C) 또는 원자번호 9 내지 35에 해당하는 할로겐인 유기염기 또는 산 부가 염 형태의 화합물.
  3. 제1항에 있어서, 유리염기 또는 산 부가 염의 형태의 [2-(2-메틸이미다졸-1-일)메틸]피리딘 화합물.
  4. 하기 일반식(Ⅱ)의 화합물을 하기 일반식(Ⅲ)의 화합물과 반응시키는 단계 및 생성된 상기 일반식(Ⅰ)의 화합물을 유리염기형태 또는 산부가 염의 형태로 회수하는 단계를 포함하는 제1항에서 정의된 일반식(Ⅰ)의 제조하는 방법.
    상기식에서, R1, R2, R3및 R4는 제1항에서 정의된 것과 같고 X는 할로겐이다.
  5. 제1항 내지 제3항중 어느 한 항에 있어서, 의약품으로서 사용하기 위한 생리학적으로 허용가능한 형태의 화합물.
  6. 제1항 내지 제3항중 어느 한 항에 의하 화합물을 생리학적으로 허용가능한 형태로 함유하며, 또한 약학적담체 또는 희석제를 함께 함유하는 약학조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920017228A 1991-09-23 1992-09-22 이미다졸릴 메틸-피리딘류 화합물 KR100254085B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4131584.7 1991-09-23
DE4131584A DE4131584A1 (de) 1991-09-23 1991-09-23 Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika

Publications (2)

Publication Number Publication Date
KR930006003A true KR930006003A (ko) 1993-04-20
KR100254085B1 KR100254085B1 (ko) 2000-09-01

Family

ID=6441240

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017228A KR100254085B1 (ko) 1991-09-23 1992-09-22 이미다졸릴 메틸-피리딘류 화합물

Country Status (24)

Country Link
EP (1) EP0534904B1 (ko)
JP (1) JP2568356B2 (ko)
KR (1) KR100254085B1 (ko)
AT (1) ATE144509T1 (ko)
AU (1) AU650569B2 (ko)
CA (1) CA2078700C (ko)
CZ (1) CZ281675B6 (ko)
DE (2) DE4131584A1 (ko)
DK (1) DK0534904T3 (ko)
ES (1) ES2092666T3 (ko)
FI (1) FI103887B1 (ko)
GR (1) GR3021444T3 (ko)
HU (2) HUT61993A (ko)
IL (1) IL103229A (ko)
MX (1) MX9205365A (ko)
MY (1) MY110450A (ko)
NO (1) NO301162B1 (ko)
NZ (1) NZ244420A (ko)
RO (1) RO109337B1 (ko)
RU (1) RU2058312C1 (ko)
SG (1) SG43079A1 (ko)
SK (1) SK279224B6 (ko)
TW (1) TW222630B (ko)
ZA (1) ZA927279B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283720B1 (ko) * 1996-12-06 2001-03-02 모리시타 요이찌 식기세정기 및 식기의 세정방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
GB0009037D0 (en) * 2000-04-13 2000-05-31 Novartis Ag Organic compounds
AU2006275824B2 (en) 2005-07-29 2010-12-16 Vanda Pharmaceuticals, Inc. Method of improving wakefulness
MX2008010322A (es) * 2006-02-13 2009-03-05 Vanda Pharmaceuticals Inc Formulaciones de dosificacion estable de imidazolilalquil-piridina s.
WO2009097416A1 (en) * 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Imidazolylalkyl- pyridines as dbh inhibitors
WO2010045342A1 (en) 2008-10-17 2010-04-22 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
JP2020520952A (ja) * 2017-05-22 2020-07-16 トーリー パインズ インスティテュート フォー モレキュラー スタディーズＴｏｒｒｅｙ Ｐｉｎｅｓ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｍｏｌｅｃｕｌａｒ Ｓｔｕｄｉｅｓ 組成物、使用方法、及び治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003732B1 (en) * 1978-02-01 1983-10-19 The Wellcome Foundation Limited Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
GB2028317B (en) * 1978-08-15 1982-11-10 Pfizer Ltd 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors
US4634711A (en) * 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283720B1 (ko) * 1996-12-06 2001-03-02 모리시타 요이찌 식기세정기 및 식기의 세정방법

Also Published As

Publication number Publication date
CA2078700C (en) 2005-09-13
EP0534904B1 (de) 1996-10-23
ATE144509T1 (de) 1996-11-15
NZ244420A (en) 1995-07-26
SG43079A1 (en) 1997-10-17
TW222630B (ko) 1994-04-21
ES2092666T3 (es) 1996-12-01
HU211261A9 (en) 1995-11-28
IL103229A0 (en) 1993-02-21
RU2058312C1 (ru) 1996-04-20
DE4131584A1 (de) 1993-03-25
FI924233A0 (fi) 1992-09-21
JP2568356B2 (ja) 1997-01-08
MY110450A (en) 1998-05-30
CZ289692A3 (en) 1993-04-14
SK289692A3 (en) 1998-08-05
MX9205365A (es) 1993-03-01
DE59207425D1 (de) 1996-11-28
EP0534904A1 (de) 1993-03-31
FI103887B (fi) 1999-10-15
JPH05194491A (ja) 1993-08-03
ZA927279B (en) 1994-03-23
RO109337B1 (ro) 1995-01-30
AU2522692A (en) 1993-03-25
AU650569B2 (en) 1994-06-23
KR100254085B1 (ko) 2000-09-01
HUT61993A (en) 1993-03-29
NO301162B1 (no) 1997-09-22
FI924233A (fi) 1993-03-24
IL103229A (en) 1996-09-12
FI103887B1 (fi) 1999-10-15
DK0534904T3 (da) 1996-11-18
CZ281675B6 (cs) 1996-12-11
SK279224B6 (sk) 1998-08-05
CA2078700A1 (en) 1993-03-24
NO923653D0 (no) 1992-09-21
NO923653L (no) 1993-03-24
HU9202886D0 (en) 1992-11-30
GR3021444T3 (en) 1997-01-31

Similar Documents

Publication Publication Date Title
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
KR910002802A (ko) 1,2,3,4-테트라히드로-9-아크리딘아민의 유도체
KR960007592A (ko) 신규한 피롤로카바졸
KR930006003A (ko) 이미다졸릴메틸-피리딘류 화합물
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
ZA889023B (en) 2-(piperazinyl)-2-oxoethylene substituted flavonoid derivatives,processes for preparing them and pharmaceutical compositions containing them
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
AU608643B2 (en) Novel derivatives of the oxime of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde, the process for their preparation, their use as medicaments and the compositions containing them
ATE70838T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
ATE82972T1 (de) Thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
KR920005720A (ko) 피리딘 유도체 그 제조방법 및 그 약학적 조성물
KR920002564A (ko) N-알킬 티아졸리딘 유도체
KR920002594A (ko) 5-이소티아졸아민 유도체
KR910014369A (ko) 이미다졸릴 프로필 구아니딘 유도체와 그 제조방법 및 이를 함유하는 약학적 조성물
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
KR930017906A (ko) 술포닐벤질 치환 이미다조피리딘
ZA909557B (en) Substituted benzothiazolinones,process for preparing these and pharmaceutical compositions containing them
DE69105618D1 (de) Derivate des 1,2,5,6-Tetrahydropyridin-3-caboxaldehydoxims, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
KR920016428A (ko) 신규 피라졸 유도체, 이의 제조방법 및 이를 함유하는 제초제 조성물

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee